We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 6 for:    emactuzumab
Previous Study | Return to List | Next Study

Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT) (TANGENT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05417789
Recruitment Status : Active, not recruiting
First Posted : June 14, 2022
Last Update Posted : September 26, 2022
Information provided by (Responsible Party):
SynOx Therapeutics Limited

Brief Summary:

This is a multicenter, Phase 3, randomised, double-blind, placebo-controlled study, which aims to evaluate the efficacy and safety of the investigational drug emactuzumab for the treatment of patients with localized or diffuse TGCT where surgical removal of the tumor is not viewed as an option.

The study consists of two parts. In Part 1, eligible subjects will be assigned in a 2:1 ratio to receive either emactuzumab or matching placebo in a double-blind fashion, that will be administered in total 5 times as an intravenous (i.v.) infusion once every 2 weeks. This will be followed by an observation period of 3 months leading to a total duration of 24 weeks in Part 1. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. Part 2 is a long-term double-blind follow-up phase of the subjects on emactuzumab or placebo. Subjects assigned to placebo in Part 1 have the option to crossover under certain circumstances to receive open-label emactuzumab in Part 2.

Condition or disease Intervention/treatment Phase
TGCT Drug: Emactuzumab Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 128 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Randomized, Placebo-controlled, Double-Blind Study of Emactuzumab to Assess Efficacy and Safety in Subjects With Tenosynovial Giant Cell Tumor (TANGENT)
Actual Study Start Date : July 18, 2022
Estimated Primary Completion Date : December 31, 2023
Estimated Study Completion Date : September 30, 2025

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Group 1 in Part 1/Part 2: Emactuzumab
Group 1: Subjects receiving emactuzumab administered on Day(D)1 and repeated once every two weeks (Q2W) for a total of 5 times, followed by an observation period of 3 months leading to a total period of 24 weeks in Part 1 and continued with a follow-up phase in Part 2.
Drug: Emactuzumab
Emactuzumab administered once every 2 weeks (q2w)

Placebo Comparator: Group 2 in Part 1 and Part 2: Placebo
Group 2: Subjects receiving placebo administered as iv infusion on D1 and repeated once every two weeks (Q2W) for 5 times followed by an observation period of 3 months to a total period of 24 weeks in Part 1 will have the option to crossover under certain circumstances to open-label emactuzumab once every 2 weeks (Q2W) for a total of 5 times in Part 2.
Drug: Placebo
Matching placebo administered once every 2 weeks (q2w)

Primary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: Day 0 - Day 180 (6 months) ]
    Objective Response Rate (ORR = complete response [CR] + partial response [PR]) by 6 months from initiation of therapy assessed by central read using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1

Secondary Outcome Measures :
  1. Physical Function [ Time Frame: up to 24 months ]
    Change in Patient-Reported Outcomes Measurement Information System Physical Function (PROMIS-PF) TGCT from baseline to 6 months

  2. Range of Motion (ROM) [ Time Frame: up to 24 months ]
    Mean change from baseline in active ROM of the joint over time

  3. Worst Stiffness [ Time Frame: up to 24 months ]
    Mean change from baseline in the Worst Stiffness Numeric Rating Scale (NRS) score over time

  4. Worst Pain [ Time Frame: up to 24 months ]
    Mean change in Pain Numerical Rating Scale (NRS) from baseline over time

  5. Quality of Life (QoL) [ Time Frame: up to 24 months ]
    Change in EuroQol 5-dimension, 5-level questionnaire (EQ-5D-5L)

  6. Duration of response (DoR) [ Time Frame: up to 24 months ]
    Duration of response (DoR) as measured by RECIST version 1.1

  7. Tumour volume score (TVS) [ Time Frame: up to 24 months ]
    Change in Tumour volume score (TVS)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age >12 years
  • Biopsy-confirmed (standard of care diagnosis history) local or diffuse TGCT where surgical resection would be associated with predicted worsening functional limitations through surgical joint damage, and/or subject has an anticipated high risk of early recurrence as determined by a multidisciplinary tumour board or equivalent, or any other morbidity associated with the surgery, and/or surgical treatment is not expected to improve the clinical outcomes of the subject.
  • Adequate organ and bone marrow function
  • If a woman of childbearing potential (WOCBP), must have a negative pregnancy test prior to starting treatment and agree to use a highly effective method of contraception
  • Participants must have written consent

Exclusion Criteria:

  • If a female, the subject is pregnant or breast feeding.
  • Medical conditions, including auto-immune, requiring systemic immunosuppression. Any systemic treatment for these conditions (eg, glucocorticoids) is not allowed within 4 weeks of Screening and during the study.
  • Known metastatic TGCT or other active cancer that requires concurrent or planned treatment
  • Received therapy for TGCT within 4 weeks prior to screening and 3 months prior to screening for pexidartinib
  • Unresolved clinically significant toxicity from a previous treatment or any history of serious liver toxicity.
  • Current or chronic history of liver disease.
  • Inadequate renal and liver function
  • Systemic antiretroviral therapy within 3 months of baseline
  • Within 6 months of baseline has experienced: clinically significant myocardial infarction, severe/unstable angina pectoris, congestive heart failure New York Heart Association (NYHA) Class III or IV, or pulmonary disease (NYHA Criteria 1994)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05417789

Layout table for location information
United States, District of Columbia
Medstar Washington Hospital Center
Washington, District of Columbia, United States, 20010-3017
United States, Maryland
Medstart Heart and Vascular Institute
Baltimore, Maryland, United States, 21237
Sponsors and Collaborators
SynOx Therapeutics Limited
Layout table for investigator information
Principal Investigator: Jean Y Blay, Prof, MD Comprehensive Cancer Centre of Lyon
Layout table for additonal information
Responsible Party: SynOx Therapeutics Limited
ClinicalTrials.gov Identifier: NCT05417789    
Other Study ID Numbers: SNX-301-02
First Posted: June 14, 2022    Key Record Dates
Last Update Posted: September 26, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Summary (synopsis) of the CSR

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by SynOx Therapeutics Limited:
TGCT, Tenosynovial Giant Cell Tumour
PVNS, Pigmented Villonodular Synovitis
Local TGCT
Diffuse TGCT
Additional relevant MeSH terms:
Layout table for MeSH terms
Giant Cell Tumors
Giant Cell Tumor of Tendon Sheath
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Joint Diseases
Musculoskeletal Diseases
Muscular Diseases